Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer

Head & Neck ◽  
2004 ◽  
Vol 27 (1) ◽  
pp. 36-43 ◽  
Author(s):  
Gabriele K. Beckmann ◽  
Florian Hoppe ◽  
Leo Pfreundner ◽  
Michael P. Flentje
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Accelerated Radiotherapy ◽  
Weekly Cisplatin

Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer

2013 ◽  
Vol 190 (3) ◽  
pp. 250-255 ◽  
Author(s):  
V. Budach ◽  
E.-T. Becker ◽  
D. Boehmer ◽  
H. Badakhshi ◽  
U. Jahn ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Accelerated Radiotherapy ◽  
Weekly Cisplatin

8511 Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head and neck cancer

2009 ◽  
Vol 7 (2) ◽  
pp. 473
Author(s):  
H. Rutten ◽  
L.A.M. Pop ◽  
G.O.R.J. Janssens ◽  
R.P. Takes ◽  
S. Knuijt ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Accelerated Radiotherapy ◽  
Weekly Cisplatin

Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study

2015 ◽  
Vol 54 (7) ◽  
pp. 1001-1007 ◽  
Author(s):  
Jens Bentzen ◽  
Kasper Toustrup ◽  
Jesper Grau Eriksen ◽  
Hanne Primdahl ◽  
Lisbeth Juhler Andersen ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Phase Ii ◽  
Neck Cancer ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Advanced Head ◽  
Accelerated Radiotherapy ◽  
Weekly Cisplatin

scholarly journals Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer

Cancer ◽  
2010 ◽  
Vol 116 (19) ◽  
pp. 4533-4540 ◽  
Author(s):  
Heather E. Newlin ◽  
Robert J. Amdur ◽  
Charles E. Riggs ◽  
Christopher G. Morris ◽  
Jessica M. Kirwan ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Altered Fractionation ◽  
Weekly Cisplatin

Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes

Oral Oncology ◽  
2022 ◽  
Vol 125 ◽  
pp. 105709
Author(s):  
Vijay Patil ◽  
Netra Ghandade ◽  
Vanita Noronha ◽  
Nandini Menon ◽  
Kumar Prabhash
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Weekly Cisplatin

Final Report of a Pilot Trial of Accelerated Radiotherapy Plus Concurrent 96-Hour Infusional Paclitaxel for Locally Advanced Head and Neck Cancer

2004 ◽  
Vol 27 (6) ◽  
pp. 595-602 ◽  
Author(s):  
Mary K. Bucci ◽  
David I. Rosenthal ◽  
Diane Hershock ◽  
James Metz ◽  
Pamela Devine ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Pilot Trial ◽  
Final Report ◽  
Advanced Head ◽  
Accelerated Radiotherapy

Comparison between weekly cisplatin-enhanced radiotherapy and cetuximab-enhanced radiotherapy in locally advanced head and neck cancer: first retrospective study in Asian population

2016 ◽  
Vol 13 (3) ◽  
pp. 195-203 ◽  
Author(s):  
Sheh Rawat ◽  
Parveen Ahlawat ◽  
Anjali Kakria ◽  
Gaurav Kumar ◽  
Ranga Rao Rangaraju ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Retrospective Study ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Asian Population ◽  
Advanced Head ◽  
Weekly Cisplatin

Retrospective comparison between high-dose cisplatin and less-intensive weekly cisplatin/paclitaxel concurrently with radiation for locally advanced head and neck cancer (LAHNC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e17535-e17535
Author(s):  
Muhammad Furqan ◽  
Muhammad Uzair Saqlain ◽  
Sarah L Mott ◽  
Ravi Patel ◽  
Douglas Earl Laux ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
High Dose ◽  
Advanced Head ◽  
Retrospective Comparison ◽  
Weekly Cisplatin

Compliance, toxicity and efficacy in weekly versus 3-weekly cisplatin concurrent chemoradiation in locally advanced head and neck cancer

2018 ◽  
Vol 18 (1) ◽  
pp. 21-25 ◽  
Author(s):  
Sandeep Muzumder ◽  
Nirmala Srikantia ◽  
Ganesha Dev Vashishta ◽  
Avinash H. Udayashankar ◽  
John Michael Raj ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Concurrent Chemoradiation ◽  
Advanced Head ◽  
Flat Dose ◽  
Grade 3 ◽  
Weekly Cisplatin

AbstractAimWeekly low-dose cisplatin is routinely used in concurrent chemoradiation (CCRT) in locally advanced head and neck cancer (LAHNC), despite 3-weekly cisplatin being the standard of care. We compared compliance, toxicity and efficacy in weekly versus 3-weekly cisplatin CCRT in LAHNC.Materials and methodsIn this retrospective study, weekly cisplatin 50 mg flat dose was compared with 3-weekly cisplatin 100 mg/m2, when given in CCRT in LAHNC with curative intent. The study outcome was compliance, toxicity, loco-regional control (LRC), disease-free survival (DFS) and overall survival (OS).ResultsEighty-four patients received CCRT from January 2013 to June 2017, 40 in weekly and 44 in 3-weekly arm. There was no difference between the arms not completing scheduled radiation therapy or chemotherapy. Patient receiving 200 mg/m2 cisplatin is higher in 3-weekly arm compared with weekly arm (75 versus 40·9%; p<0·0015). Compared with 3-weekly arm, more patient in weekly arm developed grade ≥3 mucositis (52·5 versus 15·9%, p=0·0004), day care intravenous hydration (82·5 versus 38·6% <0·0001) and in-patient admission (55·0 versus 18·2%; p=0·0004). The 2-year LRC, DFS and OS in weekly versus 3-weekly arm were: 70 versus 61·4% (p=0·406); 67·5 versus 56·8% (p=0·314); 67·5 versus 61·4% (p=0·558), respectively. The median time to LRR, DFs and OS was not reached.ConclusionsWeekly cisplatin is comparable with 3-weekly cisplatin in terms of compliance, disease control and survival, but with increased grade 3 mucositis and higher admissions for supportive care.

Sign in / Sign up

Export Citation Format

Share Document